Voyager Acquisition Corp. has announced an update to its previously disclosed Business Combination Agreement with Veraxa Biotech AG, initially announced in April 2025. According to a recent filing, Voyager has entered into a Joinder Agreement with Veraxa, PubCo, and Veraxa Cayman Merger Sub. This agreement integrates PubCo and Merger Sub into the original business combination deal, ensuring they are fully bound by its terms. The Joinder Agreement also outlines the process for transferring assets and liabilities to Merger Sub and the subsequent contribution of Merger Sub shares to PubCo. Additionally, it confirms the ownership structure and management of PubCo and Merger Sub as of the agreement's date.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.